Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Case–Control Study

Digestive Diseases and Sciences

Volumn 61, Issue 1, 2016, Pages 255-264

  Dik, Vincent K ^a   van Oijen, Martijn G H ^a,b   Smeets, Hugo M ^a,c   Siersema, Peter D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Achmea Health Insurance ^*  (Netherlands)

Author keywords

Antibiotics; Colorectal cancer; Microbiota; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE; ANTILIPEMIC AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; IMIDAZOLE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; NITROFURAN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TREATMENT DURATION; CHEMISTRY; CHI SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DYSBIOSIS; FACTUAL DATABASE; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; STATISTICAL MODEL; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DYSBIOSIS; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84952975031     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3828-0     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
2. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005;365:153–165.
3. World Cancer Research Fund/American Institute for Cancer Research. Systematic Literature Review Continuous Update Project Report. 2011 (Ref Type: Internet Communication).
4. Sommer F, Backhed F. The gut microbiota—masters of host development and physiology. Nat Rev Microbiol. 2013;11:227–238.
5. Augenlicht LH, Mariadason JM, Wilson A, et al. Short chain fatty acids and colon cancer. J Nutr. 2002;132:3804S–3808S.
6. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut. 1994;35:S35–S38.
7. Cox MA, Jackson J, Stanton M, et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World J Gastroenterol. 2009;15:5549–5557.
8. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003;133:2485S–2493S.
9. Ebert MN, Klinder A, Peters WH, et al. Expression of glutathione S-transferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate. Carcinogenesis. 2003;24:1637–1644.
10. Greer JB, O’Keefe SJ. Microbial induction of immunity, inflammation, and cancer. Front Physiol. 2011;1:168.
11. Kim YS, Milner JA. Dietary modulation of colon cancer risk. J Nutr. 2007;137:2576S–2579S.
12. Nguyen KA, Cao Y, Chen JR, et al. Dietary fiber enhances a tumor suppressor signaling pathway in the gut. Ann Surg. 2006;243:619–625.
13. Rodriguez-Cabezas ME, Galvez J, Lorente MD, et al. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr. 2002;132:3263–3271.
14. Waldecker M, Kautenburger T, Daumann H, et al. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem. 2008;19:587–593.
15. Ou J, Carbonero F, Zoetendal EG, et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr. 2013;98:111–120.
16. Vipperla K, O’Keefe SJ. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Pract. 2012;27:624–635.
17. Wells JE, Hylemon PB. Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces. Appl Environ Microbiol. 2000;66:1107–1113.
18. Ou J, Delany JP, Zhang M, et al. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr Cancer. 2012;64:34–40.
19. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105:1907–1911.
20. Balamurugan R, Rajendiran E, George S, et al. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23:1298–1303.
21. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 2011;6:e16393.
22. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol. 2011;64:424–430.
23. WHO Collaborating Centre for Drug Statistics Methodology. 2012. http://www.whocc.no.
24. Dutch National Guideline for Colon Cancer. CBO; 2008.
25. Dutch National Guideline for Rectal Cancer. CBO; 2008.
26. Kilkkinen A, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer. 2008;123:2152–2155.
27. Candela M, Turroni S, Biagi E, et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 2014;20:908–922.
28. Wang JL, Chang CH, Lin JW, et al. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int J Cancer. 2014;135:956–967.
29. Snyder RD. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environ Mol Mutagen. 2009;50:435–450.
30. Attur MG, Patel RN, Patel PD, et al. Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. J Immunol. 1999;162:3160–3167.
31. Dixon DA, Blanco FF, Bruno A, et al. Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res. 2013;191:7–37.
32. Didham RC, Reith DM, McConnell DW, et al. Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat. 2005;92:163–167.
33. Kato I, Koenig KL, Baptiste MS, et al. History of antibiotic use and risk of non-Hodgkin’s lymphoma (NHL). Int J Cancer. 2003;107:99–105.
34. Tamim HM, Hajeer AH, Boivin JF, et al. Association between antibiotic use and risk of prostate cancer. Int J Cancer. 2010;127:952–960.
35. Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. JAMA. 2004;291:827–835.
36. Zhang H, Garcia Rodriguez LA, Hernandez-Diaz S. Antibiotic use and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:1308–1315.
37. Risio M. The natural history of adenomas. Best Pract Res Clin Gastroenterol. 2010;24:271–280.